NCT07433517尚未招募1 期
An Early-Phase Clinical Study to Evaluate the Tolerability, Safety, and Efficacy of VGN-Ex05e in Patients With Autism Spectrum Disorder (ASD) Associated With Severe, Treatment-Resistant Self-Injurious and Aggressive Behaviors
Shanghai Jiao Tong University School of Medicine0 个研究点目标入组 6 人开始时间: 2026年4月1日最近更新:
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 6
- 主要终点
- Incidence and severity of adverse events
研究概览
简要总结
To evaluate the safety and tolerability of intracerebral injection of VGN-Ex05e in the nucleus accumbens of patients with autism spectrum disorder.
详细描述
This study is a single-center, open-label, Investigator-Initiated Trial. The entire trial is expected to enroll 6 subjects. The initial plan of this study is to explore two doses: 2.0×10^6 cells and 6.0×10^6 cells. During the trial, the SRC (Safety Review Committee) will conduct a comprehensive assessment and may adjust the dose as necessary.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 7 Years 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or Female, age >7, ≤18
- •DSM-5 diagnosis of Autism Spectrum Disorder, confirmed by ADOS-2
- •Diagnosis ≥ 2 years, with at least 6 months of unsuccessful systematic behavioral interventions or training, or those unable to undergo training;
- •Target symptoms and severity: Presence of recurrent self-injurious or aggressive behaviors within the last 3 months, with at least one of the following documented (meeting at least one criterion): Any self-injury item on the RBS-R scoring ≥ 3; Self-injury/aggression subscale of the BPI reaching one of the following criteria: frequency score ≥ 3, or severity score ≥ 3;
- •Previous use of multiple medications (one or more antipsychotics and one or more mood stabilizers) with inadequate response, or those with severe adverse reactions, or those who cannot tolerate，and have discontinued medication for more than 5 half-lives or 1 month (whichever is longer) prior to screening, with the expectation that these medications will not be re-administered during the study period;
- •Subjects/parents/guardians are able to understand the trial information, objectives, and risks as described in the informed consent form, are willing to comply with the clinical trial protocol, and can authorize the use of the subject's health information, voluntarily providing the signed and dated informed consent form;
- •Subjects/parents/guardians are willing to act as information providers for the study, providing information on the subject's health status, cognitive, and physical abilities (including providing information for scales).
- •Male and female subjects of childbearing potential must continuously and correctly use at least one highly effective method of contraception from the screening period through at least 1 year after administration.
排除标准
- •Refractory epilepsy within the last 12 months prior to screening (≥2 seizures per month or status epilepticus), or significant EEG discharges during the screening period with a high-risk assessment;
- •Co-occurring schizophrenia, bipolar disorder, or severe depressive disorder;
- •Severe cardiac, hepatic, renal, or hematologic diseases;
- •Coagulation disorders or bleeding tendencies (affecting surgical drug administration);
- •Active infection at the time of screening, requiring systemic treatment;
- •Co-occurring malignant tumors or history of tumors within the past 5 years；
- •Positive HIV antibody, active hepatitis C infection, active hepatitis B infection, syphilis positive, or active tuberculosis at the time of screening;
- •clinically significant abnormal ECG;
- •Any of the following laboratory test indicators meet the following criteria (those who meet the criteria and have a clear reason for retesting can recheck and confirm within one week): 1) Hemoglobin count is below the detection limit, or thrombocytopenia (< 100 × 10^9/L); 2) Alanine aminotransferase ≥ 3 × ULN and/or Aspartate aminotransferase ≥ 3 × ULN and/or Total bilirubin ≥ 2 × ULN; 3) Those with renal function impairment, defined as eGFR < 60 ml/min/1.73 m2; 4) Myocardial enzyme spectrum (Creatine kinase CK and Creatine kinase isoenzyme CK-MB) > 3 × ULN; 5) Any laboratory abnormal value with significant clinical significance that other researchers consider may interfere with the efficacy and safety data analysis of this study.
- •previous history of stem cell therapy or gene therapy;
- •pregnant or lactating.
- •Any history of intracranial infection or traumatic brain injury within 6 months prior to screening.
- •MRI evidence of space-occupying lesions, arteriovenous malformations, active intracranial hemorrhage or infarction, diffuse cerebral atrophy, or severe developmental malformations.
- •Prior intracranial surgical scarring that interferes with the planned trajectory to the nucleus accumbens (NAc).
- •Participation in another clinical trial within 3 months prior to screening.
- •History of severe hypersensitivity or allergic reactions to anesthetic agents or any components of the cell product.
- •Presence of cranial metallic materials or implanted devices that contraindicate MRI, cause significant imaging artifacts affecting surgical navigation, or other conditions that preclude MRI examination.
- •Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in the clinical trial.
研究组 & 干预措施
VGN-Ex05e
Experimental
Stereotactic intracerebral injection of VGN-Ex05e solution into the nucleus accumbens with 2.0×10^6 cells or 6.0×10^6 cells.
干预措施: VGN-Ex05e (Biological)
结局指标
主要结局
Incidence and severity of adverse events
时间窗: through study completion, an average of 1 year
次要结局
- change of Repetitive Behavior Scale-Revised score(through study completion, an average of 1 year)
- change of Childhood Autism Rating Scale score(through study completion, an average of 1 year)
- change of Autism Diagnostic Observation Schedule-Second Edition score(through study completion, an average of 1 year)
- change of Aberrant Behavior Checklist score(through study completion, an average of 1 year)
- change of Behavior Problems Index score(through study completion, an average of 1 year)
研究者
Yunhai Song
Chief Physician
Shanghai Children's Medical Center
相似试验
Enrolling By Invitation
不适用
Effects of Transcranial Direct Current Stimulation on Cognitive Rehabilitation in SchizophreniaSchizophreniaNCT07273175Medical University of Lodz120
招募中
不适用
Clinical Study on the Safety and Efficacy of Temporal Interference Stimulation in the Treatment of Post-Stroke AphasiaNCT07346378The First Affiliated Hospital of Anhui Medical University40
招募中
2 期
A Study to Evaluate the Safety, Efficacy, Tolerability and Pharmacokinetics of Escalating Doses of Glofitamab (RO7082859) as a Single Agent and in Combination with Obinutuzumab, Administered After a Fixed, Single Dose Pre-treatment of Obinutuzumab (Gazyva®/Gazyvaro™) in Patients with Relapsed/Refractory B-Cell Non-Hodgkin’s Lymphoma2023-505625-14-00F. Hoffmann-La Roche AG457
招募中
1 期
First-in-Human, Dose Escalation Trial of AXV-101 in BBS1-Related Retinal DegenerationRetinal DegenerationNCT07269665Axovia Therapeutics12
招募中
1 期
A Study of Lutetium [177Lu]-BL-ARC001 in Patients With Locally Advanced or Metastatic Lung Cancer, Breast Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid TumorsBreast CancerLung CancerNCT07274852Sichuan Baili Pharmaceutical Co., Ltd.22